secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jade Biosciences, Inc. (JBIO)
CIK:        0001798749
Form:       8-K/A
Filed at:   2024-07-01T23:59:59+00:00
Accession:  0001798749-24-000039
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.05
LLM model:  deepseek-v4-flash:cloud@v2

Aerovate Therapeutics to reduce nearly all workforce after ending AV-101 trial
------------------------------------------------------------------------------

- On June 25, 2024, Aerovate began workforce reduction after ending AV-101 clinical program.
- First wave: 39 employees (78% of workforce) terminated; nearly all remaining staff to be let go.
- Estimated $5.6 million in severance costs, mostly one-time, to be incurred in Q3 and Q4 2024.
- Severance contingent on separation agreements with general release of claims.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1798749/000179874924000039/0001798749-24-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1798749/000179874924000039/tmb-20240625x8ka.htm
  HTML page:      https://secwatch.observer/filing/0001798749-24-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer